预约演示
AstraZeneca picks up a friend for Tagrisso in $40M upfront deal
上市批准引进/卖出
Allorion’s EGFR inhibitor could enhance the activity of existing medicines through combination regimens—including AstraZeneca's Tagrisso.
AstraZenecaEGFR inhibitorEGFRtossing a little cash towards Allorion Therapeutics to pick up a friend for approved lung cancer meAstraZenecaTagrisso
AstraZenecacludes upfront and near-term milesAllorion Therapeutics with development and commercial mlung cancerf $500 million total possible, plus royalties, according to a Tuesday press release.
Small molecule biotech Allorion will pass a novel EGFR L858R allosteric inhibitor over to the Big Pharma to develop and commercialize globally in advanced EGFR-mutant non-small cell lung cancer (NSCLC).
The program will fit in nicely with AstraZeneca’s EGFR L858R allosteric inhibitorEGFR L858R allostericso, which is already approved for NSCLC after tumor resection with curativeadvanced EGFR-mutant non-small cell lung cancer (NSCLC)tion for several years, questions have begun to percolate about its future, as the therapy missed analyst consensus on sales by 2% in the third quarter and declined sequentially.
Tagrisso combined with chemotherapy AstraZenecaoweEGFR inhibitorEGFRpressive beTagrisson staving off tumor progression NSCLCred wittumor therapy alone in newly diagnosed, metaTagrissoGFR-mutant NSCLC in the late-stage FLAURA2 trial. Experts wanted to see an overall survival advantage, but data there are still immature.
Tagrisso’s EGFR inhibitor is designed to address mechanisms of resistance to current thtumores, Chief Scientific Officer Fang Li, PhD., said in Tuesday’s release. The tEGFRpmutant NSCLC enhance the activity of existing medicines through combination regimens—including Tagrisso, he noted.
AllorionechEGFR inhibitorEGFRich has headquarters in both Natick, Massachusetts and Guangzhou, China, has five programs in the works in cancer and autoimmune disease. The most advanced are in phase 1/2 development: ARTS-011 targeting TYK2 and ARTS-021 for CDK2.Tagrisso
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。